NRIX Nurix Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why NRIX matters now
Nurix Therapeutics, Inc. (NRIX) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.06 with -6.60% on the session and $2.00B in market capitalization; recent performance reads 1-month +15.16% and YTD -7.49%.
The latest financial table shown here is Q1 2026, with revenue of $6.3M, net income of $-87.2M, and EPS of $-0.79. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.9%.
The latest indexable market news headline is "Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $32.50; recent insider activity includes Ring Christine filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.02
P/S
21.19
EV/EBITDA
-5.50
DCF Value
$-34.18
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-139.4%
Operating Margin
-439.3%
Net Margin
-411.4%
ROE
-64.2%
ROA
-46.4%
ROIC
-57.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.3M | $-87.2M | $-0.79 |
| Q4 2025 | $13.6M | $-78.2M | $-0.82 |
| FY 2025 | $84.0M | $-264.5M | $-3.05 |
| Q3 2025 | $7.9M | $-86.4M | $-1.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.00
Target (Median)
$32.50
Target Range
$23.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.87
Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.